Veru (VERU)

• Market cap: $66M
• 1 day: -8.22%
• 5 days: -14.74%
• 1 month: -14.16%
• 3 months: -37.58%
• 6 months: -45.39%
• Year to date: -30.79%
• 1 year: -29.63%
• 5 years: -84.91%
• 10 years: -69.93%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Veru Inc is a biopharmaceutical company with a drug development program for the treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). The company is also in the late-stage development of certain drugs for the management of breast and prostate cancers. It also has a sexual health program that includes two products, ENTADFI, for the treatment of benign prostatic hyperplasia (BPH) and the FC2 Female Condom (Internal Condom). The company operates in a single segment and generates revenue from the USA which is the key revenue generating market, Brazil, and other regions.

Employees: 210

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

127% more first-time investments, than exits

New positions opened: 25 | Existing positions closed: 11

65% more repeat investments, than reductions

Existing positions increased: 38 | Existing positions reduced: 23

10% more funds holding

Funds holding: 111 [Q3] → 122 (+11) [Q4]

6% more call options, than puts

Call options by funds: $549K | Put options by funds: $517K

1.59% less ownership

Funds ownership: 40.95% [Q3] → 39.36% (-1.59%) [Q4]

19% less capital invested

Capital invested by funds: $46.1M [Q3] → $37.5M (-$8.6M) [Q4]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $3 565% upside
• Avg. target: $3 565% upside
• High target: $3 565% upside

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Yi Chen 36% 1-year accuracy 58 / 160 met price target

565% upside $3

Buy Reiterated

2 Jan 2025